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Successful bioprocess scale up requires an understanding of the microenvironment influenced by bioreactor 
parametric conditions and the effect on cellular metabolism and expression of a recombinant protein. While, 
significant understanding of best practices exists in scaling up bioprocesses, Contract Development and 
Manufacturing Organizations (CDMO) have a unique challenge in requiring a working knowledge of our 
bioreactor capabilities driven by a diverse client network and thus a need for a ready-to-implement scale up 
platform for a wide range of molecule types. An effective CDMO must be able to scale-up client platform 
processes (which differ for each client) as well as utilize its knowledge to help smaller client firms with minimal 
knowledge of scale-up. This challenge is increased for novel innovator molecules, biosimilar candidates, and 
existing mAb processes transferred from other facilities. Moreover, the addition of novel, disposable bioreactors 
makes evident the need to harmonize scale up strategies for bioreactors with different geometric characteristics 
as is typically found in manufacturing settings. 
In this work we present an integrated approach to characterizing different scale bioreactors from process 
development through manufacturing. Approaches include a combination of process mixing empirical correlations 
for scale-up dependent parameters and computational fluid dynamics (CFD) models as well as experimental 
data to enable scientific judgment on scale-up. Methodologies used to define scale up model are 
complementary and represent the starting point for characterizing bioreactors and achieved harmonization 
across scales. Discussion will be presented on strategies used to achieve comparability between CFD models, 
correlations and experimental data. Agreement between components of this approach is represented in design 
charts including mixing time, kLa and power per volume (P/V). (See Figure 1) 
The combination of strategies resulted in a structured methodology to define engineering design space for 
various processes based on models and experimental data. Successful outcomes for multiple products on 
process performance for cell culture processing such as growth, titer, metabolic performance and product 
quality attributes are compared between 2L, 20L and 2500L reactors.  
 
 
Figure 1 – Blend time design chart and experimental data for different bioreactor scales  
